Keystone Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2017
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Inflammation-Driven Cancer: Mechanisms to Therapy (J7)
Organizer(s) Fiona M. Powrie, Michael Karin and Alberto Mantovani
February 5—9, 2017
Keystone Resort • Keystone, CO USA
Discounted Abstract Deadline: Oct 6, 2016
Abstract Deadline: Nov 3, 2016
Scholarship Deadline: Oct 6, 2016
Discounted Registration Deadline: Dec 7, 2016
Sponsored by Incyte Corporation, Merck & Co., Inc. and Roche. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.
Joint Meeting:
Microbiome in Health and Disease (J8)
Summary of Meeting:
Carcinogenesis is the result of a complex interplay of cell intrinsic and extrinsic processes that promote genomic instability, sustained proliferation, resistance to apoptosis, reprogramming and reorganization of the stromal environment. An immune cell infiltrate is a characteristic feature of many tumors, and it is increasingly appreciated that immunity and inflammation are key determinants of tumor development and progression. This meeting will consider the molecular and environmental factors that shape the extensive cross-talk between immune, stromal and cancer cells in the tumor microenvironment. Positioned at the interface of cancer cell signaling, stem cells, inflammatory pathways and microbial drivers, this meeting should provide new insights into the factors that control the balance between tumor-promoting and tumor-suppressive immunity and inflammation and how this can be applied in the prevention and treatment of cancer. The meeting will attract a multi-disciplinary group of cancer cell biologists, immunologists and inflammation biologists and will be of interest to basic and clinical scientists alike.
View Scholarships/Awards
Carcinogenesis is the result of a complex interplay of cell intrinsic and extrinsic processes that promote genomic instability, sustained proliferation, resistance to apoptosis, reprogramming and reorganization of the stromal environment. An immune cell infiltrate is a characteristic feature of many tumors, and it is increasingly appreciated that immunity and inflammation are key determinants of tumor development and progression. This meeting will consider the molecular and environmental factors that shape the extensive cross-talk between immune, stromal and cancer cells in the tumor microenvironment. Positioned at the interface of cancer cell signaling, stem cells, inflammatory pathways and microbial drivers, this meeting should provide new insights into the factors that control the balance between tumor-promoting and tumor-suppressive immunity and inflammation and how this can be applied in the prevention and treatment of cancer. The meeting will attract a multi-disciplinary group of cancer cell biologists, immunologists and inflammation biologists and will be of interest to basic and clinical scientists alike.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, February 5 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 9 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 10 in order to fully experience the meeting.
SUNDAY, FEBRUARY 5
MONDAY, FEBRUARY 6
TUESDAY, FEBRUARY 7
WEDNESDAY, FEBRUARY 8
THURSDAY, FEBRUARY 9
FRIDAY, FEBRUARY 10
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, February 5 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 9 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 10 in order to fully experience the meeting.
SUNDAY, FEBRUARY 5
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address
*
Fiona M. Powrie,
University of Oxford, UK
Lisa M. Coussens,
Oregon Health & Science University, USA
Manipulating the Tumor Microenvironment in Cancer Therapy
Manipulating the Tumor Microenvironment in Cancer Therapy
08:00—09:00
Welcome and Keynote Address
*
Julie A. Segre,
National Institutes of Health, USA
Sarkis K. Mazmanian,
California Institute of Technology, USA
The Gut-Microbiome-Brain Connection in Neurological Diseases
The Gut-Microbiome-Brain Connection in Neurological Diseases
09:00—11:15
Inflammation-Driven Cancer
*
Michael Karin,
University of California, San Diego, USA
Fiona M. Powrie,
University of Oxford, UK
Inflammation-Driven Cancer: Host and Microbial Pathways
Inflammation-Driven Cancer: Host and Microbial Pathways
Coffee Break
Mathias Florian Heikenwälder,
German Cancer Research Center, DKFZ, Germany
On the Role of Immune Cells in NASH and NASH to HCC Transition
On the Role of Immune Cells in NASH and NASH to HCC Transition
Arthur Kaser,
University of Cambridge, UK
ER Stress and Colorectal Cancer
ER Stress and Colorectal Cancer
Jeonghyun Ahn,
University of Miami, USA
Short Talk: The Role of STING in Suppressing Inflammation-Driven Intestinal Tumorigenesis
Short Talk: The Role of STING in Suppressing Inflammation-Driven Intestinal Tumorigenesis
09:00—11:15
Monitoring Microbiome to Predict Disease Risk
*
William Michael Dunne,
bioMérieux, Inc., USA
Hera Vlamakis,
Broad Institute, USA
IBD, Crohn’s Microbiome
IBD, Crohn’s Microbiome
Coffee Break
Dan R. Littman,
HHMI/New York University School of Medicine, USA
Regulation of T Cell Responses by Microbiota
Regulation of T Cell Responses by Microbiota
Curtis C. Harris,
NCI, National Institutes of Health, USA
Microbiome-TP53 Gene Interaction in Human Lung Cancer
Microbiome-TP53 Gene Interaction in Human Lung Cancer
11:15—12:30
NIH Institutes' Interests in Microbiome Research
Ryan Ranallo,
NIAID, National Institutes of Health, USA
Phil J. Daschner,
NCI, National Institutes of Health, USA
Elisabet Caler,
NHLBI, National Institutes of Health, USA
Ricardo R. Cibotti,
NIAMS, National Institutes of Health, USA
Francesca Macchiarini,
NIA, National Institutes of Health, USA
14:30—16:30
Workshop 1: Inflammation-Driven Cancer
*
Mathias Florian Heikenwälder,
German Cancer Research Center, DKFZ, Germany
*
Hua E. Yu,
Beckman Research Institute, City of Hope, USA
Ryan Kolb,
University of Iowa, USA
IL-1beta Promotes Obesity-driven Breast Cancer Progression through the Upregulation of ANGPTL4 in Adipocytes
IL-1beta Promotes Obesity-driven Breast Cancer Progression through the Upregulation of ANGPTL4 in Adipocytes
Seyed Javad Moghaddam,
University of Texas MD Anderson Cancer Center, USA
Muc5ac Plays an Essential Role in Promotion of K-ras Mutant Lung Cancer by Inflammation
Muc5ac Plays an Essential Role in Promotion of K-ras Mutant Lung Cancer by Inflammation
Karen Pickering,
Beatson Institute, UK
Guanine Nucleotide Exchange Factor Vav1 Promotes Survival in Colorectal Cancer through T-Cell Activation
Guanine Nucleotide Exchange Factor Vav1 Promotes Survival in Colorectal Cancer through T-Cell Activation
Na-Young Song,
Yonsei University College of Dentistry, South Korea
Determining the Signaling Pathway of Epithelial-IKKalpha-Deletion-Mediated Symbiotic Bacterial and Fungal Infection in Carcinogenesis
Determining the Signaling Pathway of Epithelial-IKKalpha-Deletion-Mediated Symbiotic Bacterial and Fungal Infection in Carcinogenesis
Chunfeng Qu,
Cancer Institute/Hospital, Chinese Academy of Medical Sciences, China
Liver Inflammatory Macrophages in Response to Hepatitis B Virus (HBV) Proteins Promote Hepatocellular Carcinoma by Enhancing Angiogenesis through IL23/IL23R Interaction
Liver Inflammatory Macrophages in Response to Hepatitis B Virus (HBV) Proteins Promote Hepatocellular Carcinoma by Enhancing Angiogenesis through IL23/IL23R Interaction
Martina Seiffert,
German Cancer Research Center, Germany
Tumor Exosome-Derived Y RNA Activates TLR7/8 Signaling in Monocytes and Contributes to Cancer Inflammation and Immune Escape
Tumor Exosome-Derived Y RNA Activates TLR7/8 Signaling in Monocytes and Contributes to Cancer Inflammation and Immune Escape
14:30—16:30
Workshop 1: Microbiome in Health and Disease
*
Ami S. Bhatt,
Stanford University, USA
Michael C. Abt,
Sloan Kettering Institute, USA
Host Immune Response Supports Fecal Microbiota Transplant-Mediated Clearance of Clostridium Difficile Infection
Host Immune Response Supports Fecal Microbiota Transplant-Mediated Clearance of Clostridium Difficile Infection
Dingding An,
Harvard Medical School, USA
Microbial Sphingolipids Modulate Host Epithelium Homeostasis and Disease
Microbial Sphingolipids Modulate Host Epithelium Homeostasis and Disease
Naama Geva-Zatorsky,
Harvard Medical School, USA
Gut Microbiota-Host Interactions and their Immune Modulations
Gut Microbiota-Host Interactions and their Immune Modulations
Yun-Gi Kim,
Keio University, Japan
Neonatal Acquisition of Clostridia Species Controls Colonization Resistance Against Bacterial Pathogens
Neonatal Acquisition of Clostridia Species Controls Colonization Resistance Against Bacterial Pathogens
Monica Viladomiu,
Weill Cornell Medicine, USA
Functional Characterization of IgA-Targeted E. coli in Crohn's Disease-Associated Spondyloarthritis Links Mucosal Immunity with Systemic Inflammation
Functional Characterization of IgA-Targeted E. coli in Crohn's Disease-Associated Spondyloarthritis Links Mucosal Immunity with Systemic Inflammation
Xochitl Morgan,
University of Otago, New Zealand
Gut Microbiota Acquisition in New Zealand Children in Relation to Early Life Exposures Including Probiotics: A Longitudinal Analysis
Gut Microbiota Acquisition in New Zealand Children in Relation to Early Life Exposures Including Probiotics: A Longitudinal Analysis
17:00—19:15
Microbiome and Cancer (Joint)
*
Arthur Kaser,
University of Cambridge, UK
Laurence Zitvogel,
Institut Gustave Roussy, France
Microbe-Driven Anti-Tumor Immunity
Microbe-Driven Anti-Tumor Immunity
Giorgio Trinchieri,
NCI, National Institutes of Health, USA
Role of the Microbiota in Inflammation, Carcinogenesis and Cancer Therapy
Role of the Microbiota in Inflammation, Carcinogenesis and Cancer Therapy
Curtis Huttenhower,
Harvard School of Public Health, USA
Functional Analysis of Strains in the Human Gut Metatranscriptome
Functional Analysis of Strains in the Human Gut Metatranscriptome
Cynthia L. Sears,
Johns Hopkins University School of Medicine, USA
The carcinogenic potential of bacterial biofilms
The carcinogenic potential of bacterial biofilms
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Inflammation and Cancer Stem Cells
*
Owen J. Sansom,
Beatson Institute of Cancer Research, UK
Matthias Ernst,
Olivia Newton-John Cancer Research Institute, Australia
Excessive HCK Kinase Activity in the Tumor Stroma Polarizes Macrophages and Promotes Solid Malignancies
Excessive HCK Kinase Activity in the Tumor Stroma Polarizes Macrophages and Promotes Solid Malignancies
Simon J. Leedham,
University of Oxford, UK
Morphogen Signaling in Intestinal Inflammation and Carcinogenesis
Morphogen Signaling in Intestinal Inflammation and Carcinogenesis
Coffee Break
Fiona M. Watt,
King's College London School of Medicine, UK
Contribution of Different Epidermal Cell Populations to Inflammation-Associated Cancers
Contribution of Different Epidermal Cell Populations to Inflammation-Associated Cancers
Judith A. Varner,
University of California, San Diego, USA
Targeting Macrophage Signaling to Suppress Tumor Progression
Targeting Macrophage Signaling to Suppress Tumor Progression
Min-Kyung Choo,
Takeda, USA
Short Talk: p38 MAPK Functions as a Tumor Suppressor in Skin Epithelial Cells, but as a Tumor Promoter in Myeloid Cells
Short Talk: p38 MAPK Functions as a Tumor Suppressor in Skin Epithelial Cells, but as a Tumor Promoter in Myeloid Cells
Jelena Todoric,
University of California, San Diego, USA
Short Talk: A Stress Activated p62-NRF2-MDM2 Axis Drives Pancreatic Tumorigenesis
Short Talk: A Stress Activated p62-NRF2-MDM2 Axis Drives Pancreatic Tumorigenesis
08:00—11:00
Complex Microbiome Analyses
*
Julie A. Segre,
National Institutes of Health, USA
Gautam Dantas,
Washington University School of Medicine, USA
Networks of Exchanging Antibiotic Resistance Between Commensal, Environmental, and Pathogenic Bacteria
Networks of Exchanging Antibiotic Resistance Between Commensal, Environmental, and Pathogenic Bacteria
Coffee Break
Katherine S. Pollard,
University of California, San Francisco, USA
Decoding Cryptic Variation in the Human Microbiome
Decoding Cryptic Variation in the Human Microbiome
Kelly Wen Li Chen,
Massachusetts Institute of Technology, USA
Short Talk: Integrated Gut/Liver Microphysiological System Elucidates Cytokine/Chemokine Inter-Tissue Crosstalk under Endotoxin-Induced Stress
Short Talk: Integrated Gut/Liver Microphysiological System Elucidates Cytokine/Chemokine Inter-Tissue Crosstalk under Endotoxin-Induced Stress
14:30—16:30
Workshop 2: Inflammation and Immunity Crosstalk
*
Giorgio Trinchieri,
NCI, National Institutes of Health, USA
*
Laurence Zitvogel,
Institut Gustave Roussy, France
Giuseppe Di Caro,
University of California, San Diego, USA
Immunoglobulin A Attenuates Colonic Tumorigenesis by Controlling Microbial Translocation and Tumor-Elicited Inflammation
Immunoglobulin A Attenuates Colonic Tumorigenesis by Controlling Microbial Translocation and Tumor-Elicited Inflammation
Ankit Malik,
University of Chicago, USA
IL-33 Regulates the IgA-Microbiota Axis to Restrain IL-1alpha Dependent Colitis and Tumorigenesis
IL-33 Regulates the IgA-Microbiota Axis to Restrain IL-1alpha Dependent Colitis and Tumorigenesis
Andrea Ponzetta,
Humanitas Clinical and Research Center, Italy
Neutrophils are Protective in Cancerogenesis by Altering Tumor Microenvironment and Controlling Intestinal Microbiota
Neutrophils are Protective in Cancerogenesis by Altering Tumor Microenvironment and Controlling Intestinal Microbiota
Sabine Waeber,
Université de Lausanne, Switzerland
Mesenchymal Stem Cells from Human Squamous Cell Lung Carcinoma Modulate Natural Killer (NK) Cell Phenotype and Function
Mesenchymal Stem Cells from Human Squamous Cell Lung Carcinoma Modulate Natural Killer (NK) Cell Phenotype and Function
Martina Molgora,
Humanitas Research Hospital, Italy
Interleukin-1 Receptor 8 (IL-1R8) Plays a Crucial Role in Natural Killer Cell Differentiation and Function
Interleukin-1 Receptor 8 (IL-1R8) Plays a Crucial Role in Natural Killer Cell Differentiation and Function
Venuprasad K. Poojary,
Baylor Institute for Immunology Research, USA
A Novel Role for Itch in Inhibition of IL-17-Mediated Colon Inflammation and Tumorigenesis by ROR-gammat Ubiquitination
A Novel Role for Itch in Inhibition of IL-17-Mediated Colon Inflammation and Tumorigenesis by ROR-gammat Ubiquitination
Christoph Andreas Reichel,
Walter Brendel Centre of Experimental Medicine, Germany
Complex Formation of uPA and PAI-1 Promotes Myeloid Leukocyte Trafficking
Complex Formation of uPA and PAI-1 Promotes Myeloid Leukocyte Trafficking
14:30—16:30
Panel: The Integrative Human Microbiome Project (iHMP)
The Integrative Human Microbiome Project (iHMP) is the second phase of the National Institute of Health (NIH) Common Fund's Human Microbiome Project (HMP) program. The mission of the overall HMP is to generate resources to permit comprehensive characterization of the human microbiota to further our understanding of how the microbiome impacts human health and disease. In this phase of the program, the iHMP is creating integrated longitudinal datasets of biological properties from both the microbiome and host from three different cohort studies of microbiome-associated conditions using multiple "omics" technologies. Tools, datasets and other resources from the first phase of the project are available at the HMP DACC. The three iHMP projects have recently completed primary data generation and are entering an initial analysis phase, and this session will detail the data and resources made available to the research community by: 1) the Multi-Omic Microbiome Study: Pregnancy Initiative (MOMS-PI) at Virginia Commonwealth University, 2) the Inflammatory Bowel Disease Multi'omic Data (IBDMDB) resource from the Broad Institute and a nation-wide research tam, and 3) Integrated Personal 'Omics Profiling (IPOP) from Stanford University and the Jackson Laboratory for Genomic Medicine. For more information or to get involved with the iHMP, please see http://hmp2.org.
*
Curtis Huttenhower,
Harvard School of Public Health, USA
Jennifer M. Fettweis,
Virginia Commonwealth University, USA
George M. Weinstock,
The Jackson Laboratory, USA
Anup Mahurkar,
University of Maryland Baltimore, USA
17:00—19:00
Tumor-Elicited Inflammation
*
Ming O. Li,
Memorial Sloan Kettering Cancer Center, USA
Yinling Hu,
NCI, National Institutes of Health, USA
IKKalpha, Autoimmunity and Chronic Fungal Infection in Esophageal and Skin Carcinogenesis
IKKalpha, Autoimmunity and Chronic Fungal Infection in Esophageal and Skin Carcinogenesis
Hua E. Yu,
Beckman Research Institute, City of Hope, USA
Stat 3 in Cancer Inflammation and as a Target in Cancer
Stat 3 in Cancer Inflammation and as a Target in Cancer
Owen J. Sansom,
Beatson Institute of Cancer Research, UK
Targeting Myeloid Cells in Epithelial Cancers
Targeting Myeloid Cells in Epithelial Cancers
Elena Tosti,
Albert Einstein College of Medicine, USA
Short Talk: MMR and Tgfb Signaling Cooperate in Suppressing Inflammation-Associated Colorectal Tumorigenesis
Short Talk: MMR and Tgfb Signaling Cooperate in Suppressing Inflammation-Associated Colorectal Tumorigenesis
17:00—19:00
Human Microbiome Studies
*
Robert E.W. Hancock,
University of British Columbia, Canada
Andrew L. Goodman,
Yale School of Medicine, USA
Cooperation and Competition in the Human Gut Microbiome
Cooperation and Competition in the Human Gut Microbiome
Julie A. Segre,
National Institutes of Health, USA
Human Skin Microbiome: Topographic Functional Mapping of Healthy Volunteers and Patient Populations
Human Skin Microbiome: Topographic Functional Mapping of Healthy Volunteers and Patient Populations
Gary D. Wu,
University of Pennsylvania, USA
Diet, the Gut Microbiome and Inflammatory Bowel Disease
Diet, the Gut Microbiome and Inflammatory Bowel Disease
Renuka Nayak,
University of California, San Francisco, USA
Short Talk: Methotrexate Is an Antibacterial Drug Metabolized by Human Gut Bacteria
Short Talk: Methotrexate Is an Antibacterial Drug Metabolized by Human Gut Bacteria
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Inflammation and Immunity Crosstalk I
*
Shannon J. Turley,
Genentech, Inc., USA
Michael Karin,
University of California, San Diego, USA
Immune Crosstalk in Tumors
Immune Crosstalk in Tumors
Alberto Mantovani,
Humanitas University, Italy
Innate Immune Pathways and the Tumor Microenvironment
Innate Immune Pathways and the Tumor Microenvironment
Coffee Break
Sven Brandau,
University Hospital Essen, Germany
Short Talk: Absence of Endogenous Toll-Like Receptor Sensing Unleashes Protective Anti-Tumor Immunity and Tumor Regression
Short Talk: Absence of Endogenous Toll-Like Receptor Sensing Unleashes Protective Anti-Tumor Immunity and Tumor Regression
George Plitas,
Memorial Sloan Kettering Cancer Center, USA
Short Talk: CD177 Identifies a Novel Subset of Regulatory T Cells (Treg) Infiltrating Human Breast Cancer
Short Talk: CD177 Identifies a Novel Subset of Regulatory T Cells (Treg) Infiltrating Human Breast Cancer
08:00—11:00
Genetic Diversity and Communication
*
Thaddeus S. Stappenbeck,
Cleveland Clinic, USA
Karen Guillemin,
University of Oregon, USA
Modulation of Host Innate Immune Responses by Individual Microbiota Members
Modulation of Host Innate Immune Responses by Individual Microbiota Members
Eran Segal,
Weizmann Institute of Science, Israel
Personalized Nutrition using Gut Microbiome and Clinical Data
Personalized Nutrition using Gut Microbiome and Clinical Data
Coffee Break
Robert E.W. Hancock,
University of British Columbia, Canada
Network Biology Approaches to Understanding Inflammation
Network Biology Approaches to Understanding Inflammation
James M. Musser,
Methodist Hospital Research Institute, USA
Integrative Approach to Investigating Human Pathogen-Host Interactions: A Nightmare of Genomic Diversity?
Integrative Approach to Investigating Human Pathogen-Host Interactions: A Nightmare of Genomic Diversity?
Mahesh S. Desai,
Luxembourg Institute of Health, Luxembourg
Short Talk: A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility
Short Talk: A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility
17:00—19:00
Stromal Cells and the Tumor Microenvironment
*
Alberto Mantovani,
Humanitas University, Italy
Shannon J. Turley,
Genentech, Inc., USA
Leukocyte Function and Positioning in Diverse Stromal Niches
Leukocyte Function and Positioning in Diverse Stromal Niches
Daniel L. Worthley,
SAHMRI, Adelaide, Australia
Intestinal Mesenchyme in the Normal and Neoplastic Colon
Intestinal Mesenchyme in the Normal and Neoplastic Colon
Raghu Kalluri,
University of Texas MD Anderson Cancer Center, USA
The Functional Role of Inflammation and Fibrosis in Pancreatic Cancer
The Functional Role of Inflammation and Fibrosis in Pancreatic Cancer
17:00—19:00
Microbiome and Disease
*
Timothy K. Lu,
Massachusetts Institute of Technology, USA
Thaddeus S. Stappenbeck,
Cleveland Clinic, USA
Microbial Metabolites that Modify Intestinal Wound Repair
Microbial Metabolites that Modify Intestinal Wound Repair
Lindsay R. Kalan,
University of Wisconsin Madison, USA
Short Talk: Multi-Kingdom Microbial Communities of Chronic Non-Healing Wounds and their Association with Clinical Outcomes
Short Talk: Multi-Kingdom Microbial Communities of Chronic Non-Healing Wounds and their Association with Clinical Outcomes
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Inflammation and Immunity Crosstalk II
*
Jane L. Grogan,
Arsenal Biosciences, USA
Weiping Zou,
University of Michigan, USA
Metabolic Control of Effector T Cells and Regulatory T Cells in Tumor
Metabolic Control of Effector T Cells and Regulatory T Cells in Tumor
Thomas Gajewski,
University of Chicago, USA
Host Factors Controlling Anti-Tumor Immunity: Unexpected Impact of the Commensal Microbiota
Host Factors Controlling Anti-Tumor Immunity: Unexpected Impact of the Commensal Microbiota
Coffee Break
E. John Wherry,
University of Pennsylvania, USA
Molecular Basis of T Cell Exhaustion: Insights for Immunotherapy
Molecular Basis of T Cell Exhaustion: Insights for Immunotherapy
Martin Oft,
ARMO BioSciences, USA
PEGylated IL-10 Induces Th1 and Th2 Immunity, Proliferation of PD1+ Lag-3+ CD8+ T Cells and Multiclonal T Cell Expansion in Cancer Patients
PEGylated IL-10 Induces Th1 and Th2 Immunity, Proliferation of PD1+ Lag-3+ CD8+ T Cells and Multiclonal T Cell Expansion in Cancer Patients
Bronislaw Pytowski,
Eli Lilly, USA
Short Talk: The Effect of VEGFR2 Inhibition on Tumor Blood Vessels and Immune Landscape
Short Talk: The Effect of VEGFR2 Inhibition on Tumor Blood Vessels and Immune Landscape
08:00—11:00
Molecular Discovery of Novel Antimicrobials
*
Sean F. Brady,
Rockefeller University, USA
Andreas Peschel,
University of Tübingen, Germany
Staphylococcus Aureus in the Human Nose – A Facultative Pathogen's Interference with Microbiota
Staphylococcus Aureus in the Human Nose – A Facultative Pathogen's Interference with Microbiota
William Michael Dunne,
bioMérieux, Inc., USA
Next-Generation Antimicrobial Susceptibility Testing
Next-Generation Antimicrobial Susceptibility Testing
Coffee Break
Eric J. Alm,
Massachusetts Institute of Technology, USA
FMT Complex Analyses
FMT Complex Analyses
Silvio M. Vieira,
Yale University, USA
Short Talk: A Gut Commensal Breaches Both Gut Lymphatic and Vascular Barriers to Drive Systemic Autoimmunity
Short Talk: A Gut Commensal Breaches Both Gut Lymphatic and Vascular Barriers to Drive Systemic Autoimmunity
Jonathan L. Linehan,
NIAID, National Institutes of Health, USA
Short Talk: Cutaneous Commensal Bacteria Drive an Unconventional T Cell Response that Accelerates Wound Healing
Short Talk: Cutaneous Commensal Bacteria Drive an Unconventional T Cell Response that Accelerates Wound Healing
14:30—16:30
Workshop 3: Prevention and Therapy
*
Carola H. Ries,
Roche Innovation Center Munich, Germany
*
E. John Wherry,
University of Pennsylvania, USA
Eduardo Bonavita,
Cancer Research UK Manchester Institute, University of Manchester, UK
COX-2 Expression Positively Associates with Tumor-Promoting Inflammatory Factors and Negatively with Anti-Tumor Immune Pathways in Human Cancer
COX-2 Expression Positively Associates with Tumor-Promoting Inflammatory Factors and Negatively with Anti-Tumor Immune Pathways in Human Cancer
David N. Brindley,
University of Alberta, Canada
Blocking the Inflammatory Effects of Lysophosphatidate Signaling as a New Strategy for Decreasing Tumor Growth, Metastasis and Improving Chemotherapy
Blocking the Inflammatory Effects of Lysophosphatidate Signaling as a New Strategy for Decreasing Tumor Growth, Metastasis and Improving Chemotherapy
Feng Zhu,
NCI, National Institutes of Health, USA
Fungal Infection and Immune Dysfunction Contribute to Esophageal Carcinogenesis
Fungal Infection and Immune Dysfunction Contribute to Esophageal Carcinogenesis
Kayla Knilans,
National Institutes of Health, USA
Type 2 Signaling Improves Survival and Reduces Tumor Growth in a Mouse Model of Colitis-Associated Cancer
Type 2 Signaling Improves Survival and Reduces Tumor Growth in a Mouse Model of Colitis-Associated Cancer
Jeff Kwak,
University of Colorado Denver, USA
Complement Activation Mediates Lung Cancer Progression and Metastasis through Alterations in CD4 T Lymphocytes
Complement Activation Mediates Lung Cancer Progression and Metastasis through Alterations in CD4 T Lymphocytes
Max D. Wellenstein,
Netherlands Cancer Institute, Netherlands
Loss of p53 Drives Systemic Neutrophilic Inflammation in Breast Cancer
Loss of p53 Drives Systemic Neutrophilic Inflammation in Breast Cancer
14:30—16:30
Workshop 2: Metagenomic Analysis
*
Eric J. Alm,
Massachusetts Institute of Technology, USA
Michael G. Constantinides,
The Scripps Research Institute, USA
Mucosal-Associated Invariant T Cells Respond to Cutaneous Microbiota
Mucosal-Associated Invariant T Cells Respond to Cutaneous Microbiota
Collin Edington,
Massachusetts Institute of Technology, USA
Development of Bioreactor Devices for Microbiome and Multi-Organ Interaction Studies
Development of Bioreactor Devices for Microbiome and Multi-Organ Interaction Studies
Sho Kitamoto,
University of MIchigan Medical School, USA
Gut Inflammation-Driven Metabolic Reprograming Regulates the Competitive Fitness of Pathogenic E. coli
Gut Inflammation-Driven Metabolic Reprograming Regulates the Competitive Fitness of Pathogenic E. coli
David T. Riglar,
Harvard Medical School, USA
Gut Feelings: Engineering Synthetic Bacterial Circuits to Functionally Probe the Mammalian Gut Microbiome
Gut Feelings: Engineering Synthetic Bacterial Circuits to Functionally Probe the Mammalian Gut Microbiome
Neil Surana,
Boston Children’s Hospital, USA
Discovery of Disease-Modulating Microbiota Using Microbial Pedigree Analysis
Discovery of Disease-Modulating Microbiota Using Microbial Pedigree Analysis
Ana Weil,
Massachusetts General Hospital, USA
The Human Gut Microbiota Predicts Susceptibility to Vibrio cholerae O1 Infection
The Human Gut Microbiota Predicts Susceptibility to Vibrio cholerae O1 Infection
17:00—18:45
Prevention and Therapy
*
Fiona M. Powrie,
University of Oxford, UK
Carola H. Ries,
Roche Innovation Center Munich, Germany
Combining Macrophage Targeting with Cancer Immunotherapies
Combining Macrophage Targeting with Cancer Immunotherapies
Jane L. Grogan,
Arsenal Biosciences, USA
The Inhibitory Immunoreceptor TIGIT Limits Anti-Tumor Immunity
The Inhibitory Immunoreceptor TIGIT Limits Anti-Tumor Immunity
Jen Morton,
Cancer Research UK Beatson Institute, UK
Short Talk: Myeloid Cells as a Therapeutic Target in Pancreatic Cancer
Short Talk: Myeloid Cells as a Therapeutic Target in Pancreatic Cancer
Kristen M. Larsen,
University of South Carolina, USA
Short Talk: The Role of Interleukin 33/ST2 Axis in Liver Metastasis of Colorectal Cancer
Short Talk: The Role of Interleukin 33/ST2 Axis in Liver Metastasis of Colorectal Cancer
17:00—19:00
Systems Microbiology
*
Karen Guillemin,
University of Oregon, USA
Timothy K. Lu,
Massachusetts Institute of Technology, USA
Engineering the Microbiome
Engineering the Microbiome
James Amos-Landgraf,
University of Missouri, USA
Suppression of Tumor Growth using Biofilm Producing Sulfate-reducing Bacteria in a Rat Model of Colon Cancer
Suppression of Tumor Growth using Biofilm Producing Sulfate-reducing Bacteria in a Rat Model of Colon Cancer
Sean F. Brady,
Rockefeller University, USA
Microbial Biosynthetic Diversity
Microbial Biosynthetic Diversity
Alexandra Zhernakova,
University Medical Center Groningen, Netherlands
Short Talk: Interaction of Genetics and Food Intake Influences Gut Microbiota Composition
Short Talk: Interaction of Genetics and Food Intake Influences Gut Microbiota Composition
19:00—19:15
Meeting Wrap-Up: Outcomes and Future Directions
*
William Michael Dunne,
bioMérieux, Inc., USA
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
